A new study published in the Journal of the American Society of Nephrology sheds light on the mechanism through which an experimental drug protects kidneys from sudden damage, also known as acute kidney injury (AKI), thereby saving many lives and reducing medical costs related to the condition.
AKI, which affects millions of people worldwide and increases the risk of developing chronic kidney disease and dying early, is most often caused by reduced or blocked blood flow to the kidney (called ischemia). This can occur in many clinical situations, including shock, trauma, sepsis, heart attack, and during heart surgery. Taking high potency statins to lower cholesterol is also linked with an increased risk for AKI. Unfortunately, there are no approved drugs that reduce the incidence or severity of AKI.
Ischemia damages cells'' mitochondria, which make a form of energy called ATP that keeps cells alive and functioning. When mitochondria are damaged by ischemia, cells have a limited ability to regenerate ATP when blood flow is later restored. This causes cell death and inflammation.
In studies designed to investigate potential drug targets for AKI, Alexander Birk, PhD, Shaoyi Liu, MD, and Hazel Szeto, MD, PhD (Weill Cornell Medical College) and their colleagues recently reported that a novel agent called SS-31 (also known as Bendavia) can accelerate ATP recovery after ischemia and reduce AKI, but its mechanism of action remained unclear. Their latest research-which uses chemical, biochemical, and structural biology approaches-shows that Bendavia helps protect a unique fatty compound, or phospholipid (called cardiolipin), on the inner mitochondrial membrane that is critical in the pathway that leads to ATP production. Cardiolipin helps form the foldings of the inner mitochondrial membrane that are studded with protein complexes involved in ATP production. The loss of cardiolipin during ischemia causes mitochondria to lose their membrane folding and reduce their ability to produce ATP. Using a method called transmission electron microscopy, the researchers were able to confirm that treatment with Bendavia prior to kidney ischemia dramatically preserved mitochondrial membrane foldings and accelerated ATP recovery to protect cell structure and function.
"Recent studies have shown that AKI has more than doubled since 2000, causing nearly 39,000 deaths in 2009 alone. The discovery of a therapeutic agent that can minimize AKI will have enormous medical and economic impact," said Dr. Szeto. "Bendavia is a first-in-class mitochondria protective agent that holds promise in preventing not only AKI, but also ischemia-related injury in multiple organs," she added. Bendavia is currently being evaluated in several phase 2 clinical trials in the United States and Europe for heart and kidney disease.
In an accompanying editorial, Andrew Hall, PhD (University of Zurich, in Switzerland) wrote, "It seems clear that SS-31 can ameliorate adverse changes in mitochondrial structure and function in ischemic AKI, with the result that tubular cell structure and overall kidney function are better preserved."
Study co-authors include Yi Soong, MD, William Mills, Pradeep Singh, PhD, J. David Warren, PhD, Surya Seshan, MD, and Joel Pardee, PhD.
Disclosures: The "SS-31/Bendavia" technology is licensed for commercial research and development to Stealth Peptides International Inc... Dr. Szeto is the inventor of SS-31 and she is also the Scientific Founder of Stealth Peptides International Inc. Both Cornell Center for Technology Enterprise and Commercialization and Dr. Szeto have financial interest in Stealth Peptides International Inc. Dr. Szeto and Cornell University have a minority ownership interest in Stealth Peptides International Inc. The research was supported, in part, by the NIH (PO1-AG001751 and RO1-HL101186), and the Research Program in Mitochondrial Therapeutics at Weill Cornell Medical College that was established with a gift from Stealth Peptides International Inc.
The article, entitled "Cardiolipin as a Novel Target to Re-Energize Ischemic Mitochondria," will appear online at jasn.asnjournals.org/ on July 11, 2013, doi: 10.1681/ASN.2012121216.
The editorial, entitled "Maintaining Mitochondrial Morphology in AKI: Looks Matter," will appear online at jasn.asnjournals.org/ on July 11, 2013, doi: 10.1681/ASN.2013050519.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.Founded in 1966, and with more than 13,500 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.